Cargando…

The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

BACKGROUND: Sarcopenia was a frequent chronic complication in patients with type 2 diabetes mellitus (T2DM), and previous evidence showed conflicting results regarding the prevalence and risk factors of sarcopenia in T2DM. In the current study, we aimed at systematically exploring the prevalence and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ai, Yaqin, Xu, Ruoxin, Liu, Lingping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414692/
https://www.ncbi.nlm.nih.gov/pubmed/34479652
http://dx.doi.org/10.1186/s13098-021-00707-7
_version_ 1783747830716825600
author Ai, Yaqin
Xu, Ruoxin
Liu, Lingping
author_facet Ai, Yaqin
Xu, Ruoxin
Liu, Lingping
author_sort Ai, Yaqin
collection PubMed
description BACKGROUND: Sarcopenia was a frequent chronic complication in patients with type 2 diabetes mellitus (T2DM), and previous evidence showed conflicting results regarding the prevalence and risk factors of sarcopenia in T2DM. In the current study, we aimed at systematically exploring the prevalence and risk factors of sarcopenia in patients with T2DM. METHODS: PubMed, Embase, and Cochrane Central Register of Controlled Trials were systematically searched to identify observational studies which investigated the prevalence and risk factors of sarcopenia in patients with T2DM. The quality of individual included studies was evaluated using The Newcastle–Ottawa scale. Pooled effects regarding prevalence and associated factors were calculated using random-effects models. The potential publication bias was assessed via funnel plot and Egger test. RESULTS: Twenty-eight studies involving 16,800 patients were included in our meta-analysis. The pooled prevalence of sarcopenia in patients with T2DM was 18% (95% CI 0.15–0.22; I(2) = 97.4%). The pooled results showed that elder age (OR 4.73; 95% CI 4.30–5.19; I(2) = 85.6%), male gender, chronic hyperglycemia (higher HbA1c) (OR 1.16; 95% CI 1.05–2.47; I(2) = 99.2%) and osteoporosis (OR 1.16; 95% CI 1.05–2.47; I(2) = 99.2%) was predictors for sarcopenia, whereas patients with lower BMI (OR 1.16; 95% CI 1.05–2.47; I(2) = 99.2%) and metformin administrations (OR 1.16; 95% CI 1.05–2.47; I(2) = 99.2%) were not prone to get sarcopenia. The funnel plot and statistical tests showed no obvious publication bias. CONCLUSIONS: Sarcopenia was frequent in T2DM patients. Elder age, male gender and chronic hyperglycemia, Osteoporosis were significant risk factors for Sarcopenia. Lower BMI and metformin administrations were associated with lower risk of sarcopenia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-021-00707-7.
format Online
Article
Text
id pubmed-8414692
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84146922021-09-09 The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis Ai, Yaqin Xu, Ruoxin Liu, Lingping Diabetol Metab Syndr Research BACKGROUND: Sarcopenia was a frequent chronic complication in patients with type 2 diabetes mellitus (T2DM), and previous evidence showed conflicting results regarding the prevalence and risk factors of sarcopenia in T2DM. In the current study, we aimed at systematically exploring the prevalence and risk factors of sarcopenia in patients with T2DM. METHODS: PubMed, Embase, and Cochrane Central Register of Controlled Trials were systematically searched to identify observational studies which investigated the prevalence and risk factors of sarcopenia in patients with T2DM. The quality of individual included studies was evaluated using The Newcastle–Ottawa scale. Pooled effects regarding prevalence and associated factors were calculated using random-effects models. The potential publication bias was assessed via funnel plot and Egger test. RESULTS: Twenty-eight studies involving 16,800 patients were included in our meta-analysis. The pooled prevalence of sarcopenia in patients with T2DM was 18% (95% CI 0.15–0.22; I(2) = 97.4%). The pooled results showed that elder age (OR 4.73; 95% CI 4.30–5.19; I(2) = 85.6%), male gender, chronic hyperglycemia (higher HbA1c) (OR 1.16; 95% CI 1.05–2.47; I(2) = 99.2%) and osteoporosis (OR 1.16; 95% CI 1.05–2.47; I(2) = 99.2%) was predictors for sarcopenia, whereas patients with lower BMI (OR 1.16; 95% CI 1.05–2.47; I(2) = 99.2%) and metformin administrations (OR 1.16; 95% CI 1.05–2.47; I(2) = 99.2%) were not prone to get sarcopenia. The funnel plot and statistical tests showed no obvious publication bias. CONCLUSIONS: Sarcopenia was frequent in T2DM patients. Elder age, male gender and chronic hyperglycemia, Osteoporosis were significant risk factors for Sarcopenia. Lower BMI and metformin administrations were associated with lower risk of sarcopenia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-021-00707-7. BioMed Central 2021-09-03 /pmc/articles/PMC8414692/ /pubmed/34479652 http://dx.doi.org/10.1186/s13098-021-00707-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ai, Yaqin
Xu, Ruoxin
Liu, Lingping
The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
title The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
title_full The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
title_fullStr The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
title_full_unstemmed The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
title_short The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
title_sort prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414692/
https://www.ncbi.nlm.nih.gov/pubmed/34479652
http://dx.doi.org/10.1186/s13098-021-00707-7
work_keys_str_mv AT aiyaqin theprevalenceandriskfactorsofsarcopeniainpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis
AT xuruoxin theprevalenceandriskfactorsofsarcopeniainpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis
AT liulingping theprevalenceandriskfactorsofsarcopeniainpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis
AT aiyaqin prevalenceandriskfactorsofsarcopeniainpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis
AT xuruoxin prevalenceandriskfactorsofsarcopeniainpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis
AT liulingping prevalenceandriskfactorsofsarcopeniainpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis